Mercer Global Advisors
BCRX icon

Mercer Global Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mercer Global Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$615K Buy
61,472
+51,453
+514% +$465K ﹤0.01% 2108
2026
Q1 		$95.4K Buy
+10,019
New +$77.8K ﹤0.01% 3031
2025
Q4 		– Sell
-10,613
Closed -$80.6K – 2851
2025
Q3 		$80.6K Buy
+10,613
New +$88.4K ﹤0.01% 2552

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Mercer Global Advisors's BCRX Position: Q2 2026 in Review

Mercer Global Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 514% in Q2 2026, buying an estimated $465K and bringing the position to 61,472 shares worth $615K. The position accounts for ﹤0.01% of the portfolio, ranked #2108.

Mercer Global Advisors first reported a position in BCRX in Q3 2025 and has held it in 3 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Mercer Global Advisors held 61,472 shares of BioCryst Pharmaceuticals worth $615K as of Q2 2026.
  • Mercer Global Advisors bought 51,453 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $465K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2108 holding.
  • Mercer Global Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.